Published on 24/12/2025
Harnessing Decentralized Clinical Trials to Improve Access in Rare Disease Research
The Rationale for Decentralization in Rare Disease Trials
Rare disease trials face one central challenge: patient scarcity scattered across vast geographies. Traditional site-based clinical trials often fail to recruit sufficient participants due to travel limitations, disease burden, or lack of specialized centers near patients. Decentralized Clinical Trials (DCTs)—which integrate remote, digital, and home-based trial components—offer a transformative solution.
DCTs eliminate the need for patients to live near or travel frequently to clinical sites. This is particularly advantageous in ultra-rare conditions, where eligible patients may be located across countries or continents. By shifting clinical activities to the patient’s home or local setting, DCTs increase participation feasibility, reduce patient burden, and support patient-centric research designs.
Regulatory agencies, including the FDA and EMA, have embraced DCTs, especially during the COVID-19 pandemic. They have since issued guidance to support the continued use of decentralized models where appropriate—especially in rare disease research where accessibility is a critical factor in trial success.
Core Components of a Decentralized Rare Disease Trial
A well-designed decentralized trial for a rare disease may include a blend of virtual and on-site elements to maximize
- Telemedicine Visits: Virtual clinical consultations for enrollment, follow-up, or AE monitoring
- eConsent Platforms: Digital informed consent tools with multilingual or pediatric customization
- Direct-to-Patient Shipment: Delivery of study drugs or kits to patient homes
- Wearable Devices: Continuous monitoring of physiological endpoints (e.g., motor activity, sleep patterns)
- Mobile Healthcare Providers: Nurses conducting in-home sample collection or assessments
These components allow sponsors to conduct research with a minimal geographic footprint while maintaining regulatory compliance and data quality.
Continue Reading: Regulatory Challenges, Real-World DCT Implementation, and Case Study Insights
Regulatory Considerations for DCTs in Rare Disease Trials
While DCTs offer significant advantages, their adoption in rare disease studies must align with regulatory expectations. The FDA’s 2023 Draft Guidance on DCTs outlines key areas of focus, such as remote data verification, informed consent documentation, and the use of digital health technologies.
EMA similarly supports decentralized models but emphasizes data protection, the need for contingency planning in case of remote failure, and consistency of medical assessments across settings. Sponsors should anticipate and address these concerns during early regulatory interactions.
- Risk-Based Monitoring: Implement centralized monitoring supported by remote data analytics
- GCP Compliance: Ensure all digital tools meet 21 CFR Part 11 or EU Annex 11 requirements
- Data Privacy: Align with GDPR and HIPAA where applicable
Early engagement with agencies through pre-IND meetings or EMA’s Innovation Task Force can help sponsors clarify DCT feasibility and protocol design before launch.
Case Study: DCT in a Pediatric Ultra-Rare Disorder
A biotech company initiated a Phase II trial for a pediatric neurodegenerative disorder (affecting fewer than 300 children globally). Traditional site-based enrollment failed due to geographic constraints and disease progression. The study was redesigned as a decentralized trial with the following components:
- Video-based neurological assessments using standardized rating scales
- Home nursing visits for blood draws and physical therapy guidance
- Parent-reported ePROs using a mobile application
- Central pharmacy distribution of investigational product with video instructions
Over 90% of eligible patients enrolled within three months. Adherence improved, and no data quality issues were raised during the FDA Type B meeting. The trial demonstrated that rare disease studies can succeed with decentralized architecture.
Opportunities: Broader Inclusion and Better Engagement
DCTs unlock new possibilities in rare disease research. Patients who were previously excluded due to mobility issues, distance, or caregiver constraints can now be included, increasing trial diversity and accelerating enrollment timelines.
- Cross-Border Enrollment: Multinational patient inclusion without added travel burden
- Improved Retention: Reduction in patient fatigue and site visit dropout
- Pediatric Flexibility: Caregiver involvement through digital diaries and video support
- Real-World Data Collection: Wearables and sensors enable continuous assessment of quality-of-life parameters
For rare disease trials with subjective or longitudinal endpoints (e.g., fatigue, sleep, developmental milestones), these technologies capture more frequent and ecologically valid data points than intermittent clinic visits.
Risks and Challenges of DCT Implementation
Despite their advantages, DCTs present several operational and methodological risks:
- Data Heterogeneity: Inconsistent data quality across sites, devices, or countries
- Tech Literacy Barriers: Not all patients or caregivers are comfortable with digital platforms
- Device Calibration: Wearables may need validation for rare disease-specific measurements
- Connectivity Issues: Internet limitations in rural or resource-limited settings
- Site Coordination: Local investigator oversight still required for GCP compliance
Mitigation strategies include hybrid trial models, extensive patient training, cloud-based audit trails, and backup site infrastructure where necessary. Importantly, patient advocacy groups can provide feedback on proposed technologies during protocol development.
Tools and Platforms Supporting Decentralization
Many sponsors partner with technology providers to implement DCT elements. Examples of tools include:
- eConsent & ePRO Platforms: Medidata, Signant Health, Castor
- Telehealth Systems: VSee, Doxy.me integrated with EDC systems
- Wearables: ActiGraph, Apple Watch, Withings for heart rate, gait, and sleep
- Remote Labs & Logistics: Marken, LabCorp Mobile, IQVIA’s home visit network
Successful implementation requires cross-functional coordination between sponsors, CROs, tech vendors, and clinical sites. Additionally, patients must be involved in early usability testing of DCT tools.
Future Outlook: Mainstreaming DCTs in Rare Trials
As regulatory clarity improves and digital technology advances, decentralized trials are expected to become standard in rare disease development. The next phase will involve:
- Validation of remote endpoints
- Development of decentralized trial-specific GCP frameworks
- Wider access to global teletrial networks
- Blockchain-based patient ID verification and data tracking
Global registries like Be Part of Research (NIHR) are increasingly integrating DCT-ready patient identification and e-consent features for rare disease recruitment, streamlining the research pathway.
Conclusion: Bridging the Gap with DCTs in Rare Disease Trials
Decentralized clinical trials present a powerful model to address the core challenges of rare disease research—geographic dispersion, low patient numbers, and heavy clinical burden. By adopting flexible, patient-centric strategies and aligning with evolving regulatory standards, sponsors can unlock access to previously unreachable populations.
Though challenges remain, the benefits of DCTs—especially for rare and pediatric disorders—outweigh the limitations when implemented thoughtfully. The future of rare disease trials lies not in more sites, but in more connection—powered by innovation, compassion, and decentralization.